Phase II Study of Lenalidomide Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Trial Profile

Phase II Study of Lenalidomide Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Feb 2018 Planned End Date changed from 1 Oct 2020 to 1 Oct 2022.
    • 12 Dec 2017 Results of 5-year follow-up and correlative exploratory analysis of immunologic biomarkers and minimal residual disease measurement, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 23 Feb 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top